Differentiated Thyroid Carcinoma: Distant Metastasis as an Unusual Sole Initial Manifestation.
Cite this article as: Dhanani R
Differentiated thyroid cancer
Faisal M
distant metastasis
neoplasm metastasis
prognosis
radioactive iodine
surgery
survival
Journal
Turkish archives of otorhinolaryngology
ISSN: 2667-7474
Titre abrégé: Turk Arch Otorhinolaryngol
Pays: Turkey
ID NLM: 101682806
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
12
02
2021
accepted:
25
05
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
ppublish
Résumé
The objective of this study was to identify the characteristic features of patients with distant metastasis as the only manifestation of well-differentiated thyroid cancers and to analyze the treatment outcomes. A retrospective review of all patients with well-differentiated thyroid cancers and distant metastasis as the sole initial presentation was carried out. Data regarding age, gender, tumor histology, site, symptoms, and treatment outcomes were collected. There were 10 patients who presented with distant metastasis as the only presentation. The mean age was 56.1 years. Eight (80%) patients had osseous metastasis, one (10%) had pulmonary and one (10%) had both. Follicular thyroid carcinoma was more common and seen in six (60%) patients. Seven (77.8%) out of nine patients had demised within five years of initial presentation. Distant metastases without a neck lump as the initial presentation of well-differentiated thyroid cancers are extremely rare. No specific guidelines are available to manage such patients due to lack of relevant data in the literature.
Identifiants
pubmed: 34713003
doi: 10.4274/tao.2021.2021-2-5
pii: 49280
pmc: PMC8527540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
188-192Informations de copyright
©Copyright 2021 by Official Journal of the Turkish Society of Otorhinolaryngology and Head and Neck Surgery.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declare no conflict of interest.
Références
Ann Surg Oncol. 2013 Apr;20(4):1329-35
pubmed: 23104708
Endocr Relat Cancer. 2011 Aug 30;18(5):R165-74
pubmed: 21632805
J Clin Endocrinol Metab. 1986 Oct;63(4):960-7
pubmed: 3745409
Cancer Biother Radiopharm. 2007 Apr;22(2):250-5
pubmed: 17600472
World J Surg. 2013 Jul;37(7):1599-605
pubmed: 23525600
Nucl Med Commun. 2009 Jul;30(7):558-64
pubmed: 19436230
J Clin Endocrinol Metab. 1988 Sep;67(3):501-8
pubmed: 3410936
Int Arch Otorhinolaryngol. 2018 Apr;22(2):167-170
pubmed: 29619107
Ann Surg Oncol. 2015 Feb;22(2):460-6
pubmed: 25192681
Cancer. 1998 Dec 15;83(12):2638-48
pubmed: 9874472
Eur Arch Otorhinolaryngol. 2017 Jul;274(7):2877-2882
pubmed: 28382395
Eur Thyroid J. 2015 Dec;4(4):260-5
pubmed: 26835430
Cancer Causes Control. 2009 Jul;20(5):525-31
pubmed: 19016336
Clin Endocrinol (Oxf). 2012 Mar;76(3):439-47
pubmed: 21950769
Clin Nucl Med. 2016 Aug;41(8):606-13
pubmed: 27124680
Ann Surg. 2010 Jan;251(1):114-9
pubmed: 19779325
Am J Surg. 1997 Nov;174(5):474-6
pubmed: 9374217